Report of Foreign Issuer (6-k)

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of: June 2020

 

Commission file number: 001-36578

 

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

 

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F ☒        Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7): ☐

 

 

  

 

 

 

 

Remote Access to Annual and Extraordinary General Meeting of Shareholders

 

On June 15, 2020, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel (the “Company”), informed its shareholders that due to continued application of regulations restricting gatherings due to COVID 19, the 2020 Annual and Extraordinary General Meeting of Shareholders of the Company (the “Annual Meeting”) on Wednesday, June 24, 2020, beginning at 4:00 p.m., Israel time, will be held remotely via Zoom. Shareholders wishing to attend the Annual Meeting will be able to participate by clicking on the link below immediately prior to or during the Annual Meeting:

 

https://us02web.zoom.us/j/84302881164

 

Or access via telephone:

 

US: [phone] or [phone]

 

South Korea: [phone]

 

Hong Kong: [phone]

 

Israel: [phone]

 

United Kingdom: [phone]

 

Meeting ID: 843 0288 1164 

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Enlivex Therapeutics Ltd.
	(Registrant)
	By:	/s/ Oren Hershkovitz
	Name:  Title:	Oren Hershkovitz Chief Executive Officer

 

Date: June 15, 2020

 

 

2